These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32736670)

  • 21. Radically different amyloid conformations dictate the seeding specificity of a chimeric Sup35 prion.
    Foo CK; Ohhashi Y; Kelly MJ; Tanaka M; Weissman JS
    J Mol Biol; 2011 Apr; 408(1):1-8. PubMed ID: 21333653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A critical role for amino-terminal glutamine/asparagine repeats in the formation and propagation of a yeast prion.
    DePace AH; Santoso A; Hillner P; Weissman JS
    Cell; 1998 Jun; 93(7):1241-52. PubMed ID: 9657156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unraveling infectious structures, strain variants and species barriers for the yeast prion [PSI+].
    Tessier PM; Lindquist S
    Nat Struct Mol Biol; 2009 Jun; 16(6):598-605. PubMed ID: 19491937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular basis for transmission barrier and interference between closely related prion proteins in yeast.
    Afanasieva EG; Kushnirov VV; Tuite MF; Ter-Avanesyan MD
    J Biol Chem; 2011 May; 286(18):15773-80. PubMed ID: 21454674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oligopeptide repeats in the yeast protein Sup35p stabilize intermolecular prion interactions.
    Parham SN; Resende CG; Tuite MF
    EMBO J; 2001 May; 20(9):2111-9. PubMed ID: 11331577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Locating folds of the in-register parallel β-sheet of the Sup35p prion domain infectious amyloid.
    Gorkovskiy A; Thurber KR; Tycko R; Wickner RB
    Proc Natl Acad Sci U S A; 2014 Oct; 111(43):E4615-22. PubMed ID: 25313080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Candida albicans Sup35p protein (CaSup35p): function, prion-like behaviour and an associated polyglutamine length polymorphism.
    Resende C; Parham SN; Tinsley C; Ferreira P; Duarte JAB; Tuite MF
    Microbiology (Reading); 2002 Apr; 148(Pt 4):1049-1060. PubMed ID: 11932450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycosylphosphatidylinositol anchoring directs the assembly of Sup35NM protein into non-fibrillar, membrane-bound aggregates.
    Marshall KE; Offerdahl DK; Speare JO; Dorward DW; Hasenkrug A; Carmody AB; Baron GS
    J Biol Chem; 2014 May; 289(18):12245-63. PubMed ID: 24627481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular basis of a yeast prion species barrier.
    Santoso A; Chien P; Osherovich LZ; Weissman JS
    Cell; 2000 Jan; 100(2):277-88. PubMed ID: 10660050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Q/N-rich, polyQ, and non-polyQ amyloids on the de novo formation of the [PSI+] prion in yeast and aggregation of Sup35 in vitro.
    Derkatch IL; Uptain SM; Outeiro TF; Krishnan R; Lindquist SL; Liebman SW
    Proc Natl Acad Sci U S A; 2004 Aug; 101(35):12934-9. PubMed ID: 15326312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro analysis of SpUre2p, a prion-related protein, exemplifies the relationship between amyloid and prion.
    Immel F; Jiang Y; Wang YQ; Marchal C; Maillet L; Perrett S; Cullin C
    J Biol Chem; 2007 Mar; 282(11):7912-20. PubMed ID: 17234629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into intragenic and extragenic effectors of prion propagation using chimeric prion proteins.
    True HL; Kalastavadi T; Tank EM
    Prion; 2008; 2(2):45-7. PubMed ID: 19098443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The physical dimensions of amyloid aggregates control their infective potential as prion particles.
    Marchante R; Beal DM; Koloteva-Levine N; Purton TJ; Tuite MF; Xue WF
    Elife; 2017 Sep; 6():. PubMed ID: 28880146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Yeast prions assembly and propagation: contributions of the prion and non-prion moieties and the nature of assemblies.
    Kabani M; Melki R
    Prion; 2011; 5(4):277-84. PubMed ID: 22052349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of randomizing the Sup35NM prion domain sequence on formation of amyloid fibrils in vitro.
    Liu Y; Wei H; Wang J; Qu J; Zhao W; Tao H
    Biochem Biophys Res Commun; 2007 Feb; 353(1):139-46. PubMed ID: 17166483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenic polyglutamine tracts are potent inducers of spontaneous Sup35 and Rnq1 amyloidogenesis.
    Goehler H; Dröge A; Lurz R; Schnoegl S; Chernoff YO; Wanker EE
    PLoS One; 2010 Mar; 5(3):e9642. PubMed ID: 20224794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analyzing the birth and propagation of two distinct prions, [PSI+] and [Het-s](y), in yeast.
    Mathur V; Taneja V; Sun Y; Liebman SW
    Mol Biol Cell; 2010 May; 21(9):1449-61. PubMed ID: 20219972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scrambled prion domains form prions and amyloid.
    Ross ED; Baxa U; Wickner RB
    Mol Cell Biol; 2004 Aug; 24(16):7206-13. PubMed ID: 15282319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleation seed size determines amyloid clearance and establishes a barrier to prion appearance in yeast.
    Villali J; Dark J; Brechtel TM; Pei F; Sindi SS; Serio TR
    Nat Struct Mol Biol; 2020 Jun; 27(6):540-549. PubMed ID: 32367069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction between yeast Sup45p (eRF1) and Sup35p (eRF3) polypeptide chain release factors: implications for prion-dependent regulation.
    Paushkin SV; Kushnirov VV; Smirnov VN; Ter-Avanesyan MD
    Mol Cell Biol; 1997 May; 17(5):2798-805. PubMed ID: 9111351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.